John W. Brooker & Co., Cp As Bio N Tech Se Transaction History
John W. Brooker & Co., Cp As
- $197 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding BNTX
# of Institutions
357Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$1 Billion0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$545 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$526 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$229 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$218 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $29.3B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...